TrialJournal of neurology2025

Patients' experience with and perspectives on long-term use of continuous subcutaneous infusion of foslevodopa/foscarbidopa in Parkinson's disease.

Michael Soileau et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.